RecruitingPhase 1Phase 2NCT05338931

Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

An Open-label, Single-arm, Multi-center, Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AT101 (Anti-CD19 Chimeric Antigen Receptor T Cell) in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Sponsor

AbClon

Enrollment

82 participants

Start Date

Mar 15, 2022

Study Type

INTERVENTIONAL

Conditions

B-cell Non Hodgkin Lymphoma

Summary

Determine MTD based on the safety and tolerability of AT101 and the RP2D for patients with recurrent or non-reactive B-cell NHL.

Eligibility

Min Age: 19 Years

Plain Language Summary

Simplified for easier understanding

This study is testing the safety and effectiveness of a new drug called AT101 in patients with B-cell non-Hodgkin's lymphoma (a type of blood cancer) whose cancer has come back or stopped responding to previous treatments. **You may be eligible if...** - You have been diagnosed with B-cell non-Hodgkin's lymphoma - Your cancer has progressed after standard treatments, or you cannot tolerate standard therapy - You are generally active and able to care for yourself (ECOG performance status 0 or 1) - Your blood, kidney, liver, lung, and heart function meet the required levels - Your estimated life expectancy is at least 12 weeks **You may NOT be eligible if...** - You have active infection, autoimmune conditions, or significant heart problems - You are pregnant or nursing - You have had certain other cancers or severe organ dysfunction Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.